A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following
 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5
 or 6 infection and compensated cirrhosis.
Inclusion Criteria:

 -  Screening laboratory result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or
 6 (GT1,2,4,5,6) infection

 -  Chronic HCV infection

 -  Subject must be HCV treatment-naïve or have failed prior HCV treatment

 -  Subject must have documented compensated cirrhosis and no current or past clinical
 evidence of decompensated liver disease

 Exclusion Criteria:

 -  Positive test result at screening for Hepatitis B surface antigen or anti-human
 immunodeficiency virus (anti-HIV) antibody

 -  HCV genotype performed during screening indicating co-infection with more than 1 HCV
 genotype

 -  Consideration by the investigator, for any reason, that the subject is an unsuitable
 candidate to receive ABT-493/ABT-530